Jump to content

FKW00GA

Add links
From Wikipedia, the free encyclopedia
(Redirected from Draft:FKW00GA)

FKW00GA
Clinical data
Other namesFKW-00GA; TGW00AA; TGW-00AA; TGWOOAA; TGW-OOAA
Routes of
administration		Oral[1]
Drug classSerotonin 5-HT1A receptor partial agonist; Serotonin 5-HT2A receptor antagonist[1][2]

FKW00GA, also known as TGW00AA, is a serotonin 5-HT1A receptor partial agonist and serotonin 5-HT2A receptor antagonist which is under development for the treatment of generalized anxiety disorder, social phobia (social anxiety disorder), and sexual dysfunction.[1][3][2][4][5][6] It is taken by mouth.[1]

As of June 2021, FKW00GA is in phase 2 clinical trials for generalized anxiety disorder, social phobia, and sexual dysfunction.[1][3] It has been in phase 2 clinical trials since at least 2018.[6] The drug is under development by Fabre-Kramer Pharmaceuticals.[1][3][2] FKW00GA is a small molecule, but its chemical structure does not yet seem to have been released.[1][3]

References

[edit]
  1. ^ a b c d e f g "FKW 00GA". AdisInsight. 15 June 2021. Retrieved 29 October 2024.
  2. ^ a b c Sartori SB, Singewald N (December 2019). "Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders". Pharmacology & Therapeutics. 204: 107402. doi:10.1016/j.pharmthera.2019.107402. PMID 31470029.
  3. ^ a b c d "Delving into the Latest Updates on TGW00AA with Synapse". Synapse. 19 September 2024. Retrieved 29 October 2024.
  4. ^ Farmer M, Yoon H, Goldstein I (August 2016). "Future Targets for Female Sexual Dysfunction". The Journal of Sexual Medicine. 13 (8): 1147–1165. doi:10.1016/j.jsxm.2016.05.016. PMID 27436073.
  5. ^ Fagan HA, Baldwin DS (June 2023). "Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions". Expert Review of Neurotherapeutics. 23 (6): 535–548. doi:10.1080/14737175.2023.2211767. PMID 37183813.
  6. ^ a b Staroń J, Bugno R, Hogendorf AS, Bojarski AJ (September 2018). "5-HT1A receptor ligands and their therapeutic applications: review of new patents". Expert Opinion on Therapeutic Patents. 28 (9): 679–689. doi:10.1080/13543776.2018.1514011. PMID 30124346.


Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=FKW00GA&oldid=1255779981"